SWOG clinical trial number
S1221

"Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer."

39% Accrual
Accrual
39%
Closed
Phase
39% Accrual
Accrual
39%
Abbreviated Title
BRAF Mutant Metastatic Cancer
Status Notes
The study referenced above was temporarily closed to accrual on 10/31/2016.
Due to drug supply on this study, the study will be switched from temporarily closed to permanently closed with the same status date of 10/31/2016.
Activated
07/01/2013
Participants
Limited: Institutions Listed on the Title Page

Research committees

Melanoma
Gastrointestinal Cancer
Leukemia

Treatment

Dabrafenib GSK2141795 Trametinib Dimethyl Sulfoxide